Autolomous

We were thrilled to attend Advanced Therapies Integrates 2024, organised by Life Science Integrates, hosted at GSK. The event's focus on "Digital Revolution & A Person-Centric Approach" resonated deeply with our mission at Autolomous. Through engaging fireside chats and panel discussions, industry experts, patient advocates, and technology providers shared their perspectives on the transformative power of technology in advancing advanced therapies. Key takeaways include: 👉 Digitization, predictive analytics, robotics, and digital twins are poised to reduce costs and expedite therapy development. High-quality data is essential to maximize the potential of these tools and early-stage planning for data collection, storage, and management is crucial. 👉 The industry must invest in upskilling and reskilling initiatives to bridge the skills gap. Our visit to the Cell and Gene Therapy Catapult Skills Training Lab Centre highlighted the crucial role of practical training in addressing this gap in cell and gene therapy. 👉 Involving patients in decision-making processes, ensuring access to information, and addressing their unique needs and concerns throughout the development and delivery of therapies is crucial By harnessing the power of technology and fostering collaboration, we can accelerate the development of life-changing therapies. #AdvancedTherapies #CellTherapies #GeneTherapies

🩺 Alexander Seyf (Autolomous) speaks to IBTV about equitable patient access, the importance of having the patient at the center of therapeutic development, and about how Autolomous is utilizing software in order to empower patient-centric programs. ▶️ Watch the full interview below, or catch up on all the insights from Mesa, here: https://lnkd.in/eF-SM8pq #CGT #CellTherapy #GeneTherapy #AdvancedTherapies #CGMesa24 #PatientAccess #PatientCentricity

Check out the latest cell and gene therapy sector insights from Alliance for Regenerative Medicine! Their report for Q3 of 2024 deep dives into data about the ongoing clinical trials, therapeutic developers, and total sector investment.

Last week, Autolomous’s COO, Walid Fahme, and Head of Partnerships, James Rutley, had the pleasure of attending BioProcess UK 2024 BioIndustry Association (BIA). This insightful event offered a unique platform to connect with industry leaders, explore cutting-edge technologies, and gain valuable insights into the future of the UK’s biotech sector. Key themes that emerged from the conference included: 👉 Sustainability and environmental impact came out as a major theme, particularly in the context of the recent iUK grant calls 👉 The state of the industry in the last 12 months was met with enthusiasm and confidence in the year ahead, in spite of economic challenges 👉 The iUK Innovation Zone displayed some of the trail-blazing work being done with government support, highlighting novel & digital technologies and collaborations 👉 Cell and gene therapy was a focal topic of the dialogue, featuring in panel sessions and discussions. There is a strengthening belief that the UK can play a pivotal role in this space We at Autolomous are inspired by the future of UK's cell and gene therapy field and are committed to playing our part in its evolution. #bioProcessUK #CGT #Innovation

Last Thursday, we had the pleasure of attending the Swedish Chamber of Commerce for the UK networking event, graciously hosted by Hästens Beds. This provided an excellent opportunity to connect with fellow members from a variety of industries and formally introduce Autolomous as one of the newest members. We are grateful for the chance to share our insights and learn from other innovative companies. We look forward to future collaborations and continued growth within the vibrant Swedish business community. Walid Fahme James Rutley Lydia Golding #SCC #collaboration

Just FOUR days to go until #AdvancedTherapiesIntegrates in Stevenage! We're looking forward to welcoming all attendees, sponsors, partners, and speakers from across the Advanced Therapies sector for an exciting opportunity to connect, share knowledge, and collaborate to drive the industry forward. Take a look at our full agenda featuring, Cell and Gene Therapy Catapult, CPI, Cytiva, Rentschler Biopharma, Mills & Reeve, AscellaHealth, Stevenage Borough Council, Labman, DLRC Regulatory Consultancy, HiTech Health , Bulb Interiors, Laboratories & Consulting, ImmuONE, IBM, MEF2C Foundation, RoslinCT, Achilles Therapeutics plc, MFX, Cellular Origins, adthera bio, Gilead Sciences, Autolomous, Newcastle University, Purespring Therapeutics, Parkwalk Advisors, OneChain Immunotherapeutics, Rinri Therapeutics, LifeArc, FUJIFILM Diosynth Biotechnologies, Stevenage Bioscience Catalyst, Complement Therapeutics  

💙 What a fantastic evening we had yesterday at Hästens Marylebone showroom, coming together for another Link Up Drinks. A heartfelt thank you to Hästens Beds for hosting us at your beautiful space, and to store manager Rodrigo Tonello and the team for your wonderful hospitality.   It was a pleasure to welcome our newest members – Autolomous, DSV - Global Transport and Logistics, MoneyWise, Moyagi, and Polarium – as they introduced themselves to the SCC UK community. A very warm welcome to you all!   And of course, thank you to everyone who joined us – the great company certainly added some extra warmth to a chilly night.   Wishing you all a fantastic Friday and an even better weekend. We look forward to seeing you again soon! 📸 See all photos from the event here: https://lnkd.in/dPugpi6n   #SCCLinkUpDrinks #Network #SwedishBritish #Event #SwedenUK #London #SCCUK

It was great to attend, alongside the rest of the Innovate UK Future Medicines team, the 21st Annual bioProcessUK Conference today in Liverpool - a key event that brought together stakeholders across the bioprocessing sector to discuss advancements in biomanufacturing. A thank you to our five Innovate UK-funded projects revolutionising medicines manufacturing that were able to come and feature in our Innovation Zone: BIOTOOLOMICS LIMITED MESOX BiologIC Technologies Intellegens Autolomous Highlights for me included the “Medicines Manufacturing Mastermind” where Stella Peace, Executive Chair for Innovate UK took to the stage to spotlight the transformative impact of strategic investments and the exciting future of UK biomanufacturing. As well as a fantastic final session chaired by Laura Griffiths: “Dragon's Den - Innovate and Automate - the Digital Advantage” where six cutting edge technologies gave their captivating pitches to compete for the audience vote. A big thank you to the BioIndustry Association (BIA) for organising such a successful event! #Biomanufacturing #MedicinesManufacturing Hareklea Markides Owen Burbidge Sarah Goulding Mark Talford Radhika Bilgi

Next week, our Head of Partnerships James Rutley will participate in the “Investing in our health” panel during #AdvancedTherapiesIntegrates. The panellists will discuss how we can ensure the UK sees ATMPs as an investment in our health and economy and get advanced therapies to the people who need them rapidly and cost-effectively. See you there! Life Science Integrates #CGT #partnership #AdvancedTherapies

A huge congratulations to PTC Therapeutics, Inc., who have been granted the first-ever FDA approval for direct-to-brain gene therapy 🎉 This approval marks a major step forward for the treatment of ultra-rare diseases, with Kebilidi being approved for AADC deficiency, a debilitating and life-threatening condition. Kebilidi is a recombinant AAV-based gene therapy that works by delivering a functional copy of the DDC gene to cells in a brain region called the putamen. This groundbreaking achievement marks a new era in gene therapy, where we're not just treating symptoms, but targeting the root cause of rare diseases. It's a real testament to the power of innovation and the unwavering dedication of scientists and researchers. 🚀 Let's continue to push the boundaries of medical science and bring hope to patients worldwide 🚀 #genetherapy #AADCdeficiency #FDAapproval